balapiravir
Balapiravir is an experimental antiviral drug which acts as a polymerase inhibitor. There were efforts to develop it as a potential treatment for hepatitis C, and it was subsequently also studied in Dengue fever, but was not found to be useful. Lower doses failed to produce measurable reductions in viral load, while higher doses produced serious side effects such as lymphopenia which precluded further development of the drug. Subsequent research found that excess cytokine production triggered by Dengue virus infection prevented the conversion of the balapiravir prodrug to its active form, thereby blocking the activity of the drug. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Dec 1, 2007 (NCT00517439)
Timeline
Indications
Mechanism of action
- RNA-directed RNA polymeraseINHIBITOR
RNA-directed RNA polymerase inhibitor
- Hepatitis C virusINHIBITOR
Hepatitis C virus inhibitor
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
Chemistry & pharmacology
SMILES
CC(C)C(=O)OC[C@@]1(N=[N+]=[N-])O[C@@H](n2ccc(N)nc2=O)[C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C- Mol. weight
- 494.51 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBalapiravir ↗
- ChEMBLCHEMBL550936 ↗
Also known as
- balapiravir
- balapiravir
- balapiravir
- balapiravir
- balapiravir
- r1626
- r 1626
- r-1626
- ro4588161
- ro4588161
- ro-4588161
- ro-4588161
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01096576 | Phase 1 | Jul 1, 2010 | Roche |
| NCT00517439 | Phase 2 | Dec 1, 2007 | Roche |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 2 | 2 | 2 | 2007 |